Virginia G. Kaklamani, MD, DSc, discusses datopotamab deruxtecan and other antibody-drug conjugates available for patients with unresectable or metastatic hormone receptor-positive, HER2-negative ...

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.

Failed to fetch dynamically imported module: https://sg.finance.yahoo.com/assets/_app/immutable/nodes/100.C0JpamNs.js ...

The trial builds off the company’s previous Phase Ia/II trial that saw an estimated survival rate of 52.4% at 24 months in ...

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced an exclusive license agreement with Lepu Biopharma Co., Ltd. (Stock ...